Im Cannabis Corp (IMCC)

$2.27

+0.03

(+1.34%)▲

Market is closed - opens 7 PM, 07 Oct 2024

Performance

  • $2.17
    $2.29
    $2.27
    downward going graph

    4.41%

    Downside

    Day's Volatility :5.24%

    Upside

    0.87%

    downward going graph
  • $1.13
    $8.10
    $2.27
    downward going graph

    50.04%

    Downside

    52 Weeks Volatility :86.0%

    Upside

    71.98%

    downward going graph

Returns

PeriodIm Cannabis CorpRussel 2000Index (Russel 2000)
3 Months
-10.9%
0.0%
0.0%
6 Months
-56.59%
0.0%
0.0%
1 Year
-42.56%
0.0%
0.0%
3 Years
-98.91%
-20.6%
-20.6%

Highlights

Market Capitalization
5.0M
Book Value
$3.17
Earnings Per Share (EPS)
-4.7
Wall Street Target Price
5.99
Profit Margin
-28.25%
Operating Margin TTM
-19.58%
Return On Assets TTM
-17.18%
Return On Equity TTM
-112.01%
Revenue TTM
49.9M
Revenue Per Share TTM
22.34
Quarterly Revenue Growth YOY
11.700000000000001%
Gross Profit TTM
9.2M
EBITDA
-11.0M
Diluted Eps TTM
-4.7
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.69
EPS Estimate Next Year
-1.34
EPS Estimate Current Quarter
-0.86
EPS Estimate Next Quarter
-0.79

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Im Cannabis Corp(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 163.88%

Current $2.27
Target $5.99

Technicals Summary

Sell

Neutral

Buy

Im Cannabis Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Im Cannabis Corp
Im Cannabis Corp
0.45%
-56.59%
-42.56%
-98.91%
-99.6%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-7.7%
-19.46%
-2.97%
11.68%
27.46%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
0.78%
25.45%
24.25%
40.35%
40.35%
Zoetis Inc.
Zoetis Inc.
2.36%
15.15%
11.04%
-2.78%
51.5%
Viatris Inc.
Viatris Inc.
-2.06%
-3.14%
17.96%
-15.33%
-30.05%
Catalent, Inc.
Catalent, Inc.
0.51%
6.98%
41.65%
-53.37%
24.81%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Im Cannabis Corp
Im Cannabis Corp
NA
NA
NA
-5.69
-1.12
-0.17
NA
3.17
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
33.7
33.7
0.26
4.57
0.16
0.12
NA
24.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
32.94
32.94
1.49
0.36
0.07
0.04
0.02
1.82
Zoetis Inc.
Zoetis Inc.
37.45
37.45
2.64
5.82
0.49
0.14
0.01
10.94
Viatris Inc.
Viatris Inc.
224.4
NA
0.07
2.68
-0.03
0.03
0.04
16.36
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.89
0.2
-0.25
0.0
NA
19.91
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Im Cannabis Corp
Im Cannabis Corp
Buy
$5.0M
-99.6%
NA
-28.25%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$11.5B
27.46%
33.7
16.0%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$48.2B
40.35%
32.94
9.66%
Zoetis Inc.
Zoetis Inc.
Buy
$87.2B
51.5%
37.45
26.29%
Viatris Inc.
Viatris Inc.
Hold
$13.6B
-30.05%
224.4
-4.24%
Catalent, Inc.
Catalent, Inc.
Hold
$11.0B
24.81%
211.02
-23.81%

Insights on Im Cannabis Corp

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 10.69M → 14.75M (in $), with an average increase of 14.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -5.62M → -3.02M (in $), with an average increase of 85.6% per quarter

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 41.6% return, outperforming this stock by 84.2%

  • Vs NBIX

    In the last 3 years, Im Cannabis Corp has experienced a drawdown of -98.9%, however Neurocrine Biosciences Inc. resisted the overall trend and outperformed by 45.5%

Institutional Holdings

  • AdvisorShares Investments, LLC

    4.63%

  • BMO Capital Markets Corp.

    0.64%

  • Bank of Montreal

    0.64%

  • Citadel Advisors Llc

    0.49%

  • Renaissance Technologies Corp

    0.37%

Company Information

premium medical cannabis products for global consumers – im cannabis (imc) is one of the world's pioneering medical-grade cannabis companies, with operations in israel, across europe, and canada. over the past decade, imc has established its premium medical cannabis brand, comprising a full spectrum of products known for their quality, consistency, and purity, such as 'roma', 'tel aviv' and 'london'. in europe, imc has established a fully operational, vertically integrated medical cannabis business, spearheaded by its eu-gmp certified distribution arm in germany and augmented by strategic alliances with certified pan-eugmp certified suppliers. to this end, imc has formed strong strategic alliances within the international medical cannabis industry, aiming for a dominant position in satisfying the global demand for high-quality medical cannabis products, which both physicians and patients can rely upon. imc further intends to leverage its expertise in israel in order to bolster its res

Organization
Im Cannabis Corp
Employees
95
CEO
Mr. Oren Shuster
Industry
Healthcare

Discover More

FAQs